These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25272429)

  • 1. Treating metastatic prostate cancer now and in the future.
    Meng MV; Boughey JC
    Bull Am Coll Surg; 2014 Sep; 99(9):55-7. PubMed ID: 25272429
    [No Abstract]   [Full Text] [Related]  

  • 2. Castration-naive metastatic prostate cancer: reshaping old paradigms.
    Ratta R; Grassi P; Fucà G; Verzoni E; Procopio G
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):879-881. PubMed ID: 28854837
    [No Abstract]   [Full Text] [Related]  

  • 3. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.
    Luo J; Beer TM; Graff JN
    Oncology (Williston Park); 2016 Apr; 30(4):336-44. PubMed ID: 27085332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone--what is wrong with the adrenal glands?
    Schmid S; Fornaro J; Rothermundt C; Omlin A; Brändle M; Rupp NJ; Gillessen S
    Clin Genitourin Cancer; 2014 Aug; 12(4):e133-7. PubMed ID: 24583161
    [No Abstract]   [Full Text] [Related]  

  • 7. Androgen Deprivation Therapy for Advanced Prostate Cancer: Can Evolution Be Accelerated?
    Mohler JL
    J Natl Compr Canc Netw; 2016 Jun; 14(6):701-3. PubMed ID: 27283162
    [No Abstract]   [Full Text] [Related]  

  • 8. New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When.
    Roviello G; Generali D
    Clin Genitourin Cancer; 2019 Jun; 17(3):e534-e535. PubMed ID: 30827924
    [No Abstract]   [Full Text] [Related]  

  • 9. First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer.
    Sena LA; Wang H; Denmeade SR
    Prostate; 2023 Sep; 83(12):1127-1132. PubMed ID: 37244750
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?
    Aggarwal RR; Ryan CJ; Chan JM
    Urol Oncol; 2013 Jul; 31(5):522-30. PubMed ID: 21658978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA; Dzik C; Rathkopf D; Scher HI
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for prostate cancer.
    Chung PH; Gayed BA; Thoreson GR; Raj GV
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):533-50. PubMed ID: 24274615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alternative antiandrogen therapy for castration-resistant prostate cancer].
    Suzuki H; Utsumi T; Endo T; Kamijima S; Kamiya N
    Nihon Rinsho; 2016 May; 74 Suppl 3():589-94. PubMed ID: 27344799
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on systemic therapy for advance prostate cancer.
    Carthon B; Rossi PJ
    Curr Probl Cancer; 2015; 39(1):52-62. PubMed ID: 25637932
    [No Abstract]   [Full Text] [Related]  

  • 16. Base of the skull metastases in metastatic castration-resistant prostate cancer.
    Bourlon MT; Glodé LM; Crawford ED
    Oncology (Williston Park); 2014 Dec; 28(12):1115-6, 1124. PubMed ID: 25510811
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial Comment to Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Shiota M
    Int J Urol; 2022 May; 29(5):478-479. PubMed ID: 35297110
    [No Abstract]   [Full Text] [Related]  

  • 18. The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer.
    Moul JW
    Oncology (Williston Park); 2014 Aug; 28(8):702-3, 722. PubMed ID: 25140628
    [No Abstract]   [Full Text] [Related]  

  • 19. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in response to Onal's letter to the editor.
    Triggiani L; Tomasini D; Mazzola R
    Med Oncol; 2021 Sep; 38(11):136. PubMed ID: 34581899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.